-
Vaccine efficacy on variants
How do we know if current vaccines will be effective against new variants?
The emerging of new COVID variants around the globe is raising concerns on whether these might blunt the efficacy of ...
-
How do COVID variants emerge?
Evidence suggests that people with weak immune systems may be accelerating mutations.
Since its first appearance in Wuhan, China, SARS-CoV2 has been acquiring random mutations. In recent months several n...
-
AstraZeneca vaccine: clot or not?
The AstraZeneca vaccine’s rollout has now been limited. Is there a clear answer as to whether it ...
In mid-March, several European countries paused the distribution of the AstraZeneca COVID-19 vaccine following report...
-
It’s worth re-engineering the clamp
UQ’s COVID-19 vaccine trial demonstrated the benefits of the molecular clamp technology.
The Australian COVID-19 vaccine developed by the University of Queensland was abandoned last December after participa...
-
Immunosuppressants and COVID-19
The divergent effect of immunosuppressive drugs in COVID-19 infection.
Immunosuppressant drugs commonly used for autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s di...
-
COVID-19 vaccines and cancer
Cancer patients are among the most vulnerable to COVID-19 infection. Are vaccines safe and effect...
People with cancer are at a higher risk of developing severe infection when they catch the SARS-CoV-2 virus. That’s b...
-
Update on AstraZeneca and blood clots
German researchers might have found the link between the COVID-19 vaccine and unusual cases of bl...
The Australian Technical Advisory Group on Immunisation (ATAGI) – the group of experts that advises the government on...
-
Common drug makes COVID worse
A treatment for inflammatory bowel disease might dampen COVID-19 immune response.
A new study, published today in the BMJ, showed that a commonly prescribed inflammatory bowel disease (IBD) drug call...
-
Halts to AstraZeneca vaccine in Europe: latest
Are European countries overreacting, or is there a cause for concern?
On Monday, Germany, France and Italy joined a group of other European countries that had temporarily stopped administ...
-
South African variant yet more concerning
Study on AstraZeneca vaccine’s efficacy against B.1.351 shows “disappointing” results.
Early in February, the South African government suspended the AstraZeneca vaccine rollout after a small-scale trial f...
-
Equitable vaccine access for all
It’s not just idealism: equal access makes everyone COVID safer.
The coronavirus pandemic has claimed the lives of more than 2.6 million people globally and disrupted everyone’s live...
-
Pain education could end the opioid crisis
Training clinicians makes them less likely to prescribe opioids in emergency departments.
Low back pain is today a leading cause of disability worldwide. It occurs across all ages, socioeconomic levels and c...
-
Global pandemic needs a global plan
While Australia and Europe squabble over vaccine doses, parts of the world are abandoned.
On Thursday, Italy blocked the export of 250,000 doses of the AstraZeneca vaccine bound for Australia. With support f...
-
Determined science
A multi-skilled, international team conducted the detailed research into the Folbigg family’s gen...
In 2003, Kathleen Folbigg was convicted of killing her four young children, who died suddenly and unexpectedly in the...
-
The jab is jumpin’
Australia’s vaccine rollout is underway. Are we on track?
The first 300,000 doses of the Oxford/AstraZeneca jab landed at Sydney airport last Sunday. The AstraZeneca vaccin...
-
South Africa concern
Questions over AstraZeneca vaccine’s efficacy against new variant.
South Africa has suspended the rollout of the AstraZeneca vaccine after a small-scale trial found that the vaccine of...
-
What’s so scary about the UK variant?
Are new COVID-19 strains a more dangerous threat?
The new highly infectious variant of SARS-CoV-2 first identified in the United Kingdom last December has landed in Au...
Read science facts, not fiction...
There’s never been a more important time to explain the facts, cherish evidence-based knowledge and to showcase the latest scientific, technological and engineering breakthroughs. Cosmos is published by The Royal Institution of Australia, a charity dedicated to connecting people with the world of science. Financial contributions, however big or small, help us provide access to trusted science information at a time when the world needs it most. Please support us by making a donation or purchasing a subscription today.
